NEW: StemSpan™ ACF, the First Plasma Component-Free Hematopoietic Expansion Media STEMCELL Technologies Inc. announced this week the launch of StemSpan™ ACF, a new animal component-free (ACF) and chemically-defined hematopoietic stem cell expansion medium, which contains no animal and human plasma-derived components. [STEMCELL Technologies Inc.] Press Release ARIAD Announces Initiation of Randomized Phase III Trial of Ponatinib in Newly Diagnosed Patients with Chronic Myeloid Leukemia ARIAD Pharmaceuticals, Inc. announced the initiation of the randomized Phase III trial of ponatinib in adult patients with newly diagnosed chronic myeloid leukemia. [ARIAD Pharmaceuticals, Inc.] Press Release Bio-Path Holdings Begins Enrollment in Fourth Cohort of Phase I Clinical Trial of Lead Product Candidate Liposomal Grb-2 in Leukemias Bio-Path Holdings, Inc. announced that it has begun enrolling patients into the fourth dosage cohort in its Phase I clinical trial of BP-100.1.01 (Liposomal Grb-2), which is being evaluated as a systemic treatment for blood cancers including acute myeloid leukemia, chronic myelogenous leukemia, acute lymphoblastic leukemia and myelodysplastic syndrome. [Business Wire] Press Release American Society of Hematology Launches Multi-Million-Dollar Grant Program to Support Critical Blood Disease Research The American Society of Hematology announced its commitment of $9 million over a three-year period to provide funding, in the form of bridge grants, for its hematologists whose vital research will not be accomplished due to the severe funding reductions for biomedical research. [American Society of Hematology] Press Release Stem Cell Agency Commits $150 Million to Develop New Therapies California’s stem cell agency, the California Institute for Regenerative Medicine approved $150 million in new funding to help move promising stem cell-based therapies from the laboratory research phase to clinical trials in people. [California Institute for Regenerative Medicine] Press Release Cleveland BioLabs Signs Contract for Approximately $4 Million with Russian Ministry of Industry and Trade for Development of CBLB612 Cleveland BioLabs, Inc. announced that it has signed a contract valued at approximately $4 million, with the Ministry of Industry and Trade of the Russian Federation for development of CBLB612, a drug in development for stimulation of hematopoietic stem cell proliferation and mobilization. [Cleveland BioLabs, Inc.] Press Release DACOGEN® Receives Positive Regulatory Recommendation in the European Union for Treatment of Acute Myeloid Leukemia Janssen-Cilag International NV announced that the Committee for Medical Products for Human Use (CHMP) of the European Medicines Agency has granted a positive opinion recommending approval of DACOGEN® for injection. The CHMP is recommending that DACOGEN be indicated for the treatment of adult patients with newly diagnosed de novo or secondary acute myeloid leukemia, who are not candidates for standard induction chemotherapy. [Business Wire] Press Release |